Merck ends two Phase 3 studies of Keytruda, including an early-stage non-small cell lung cancer trial
Merck said Thursday morning it is discontinuing two Phase 3 trials of Keytruda, the world’s top-selling medicine, after independent data monitoring …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
